American Thoracic Society International Conference 2022 (ATS 2022)

Response analysis further establishes tezepelumab benefit in severe uncontrolled asthma

Roshini Claire Anthony, 20220627150001

Adolescents and adults with severe uncontrolled asthma while on inhaled corticosteroids (ICS) had greater responses to the human monoclonal antibody tezepelumab than placebo, according to prespecified exploratory results of the phase III NAVIGATOR trial.

COPD tied to earlier lung cancer diagnosis

Audrey Abella, 20220627100000

Chronic obstructive pulmonary disease (COPD) is associated with an earlier diagnosis of lung cancer, according to a cross-sectional, real-world study.

Fixed-dose albuterol/budesonide an effective rescue med in moderate-to-severe asthma

Roshini Claire Anthony, 20220615180001

A fixed-dose combination of albuterol and budesonide, delivered as needed, reduced the risk of severe exacerbations in patients with moderate-to-severe asthma inadequately controlled with corticosteroid maintenance therapy, according to results of the phase III MANDALA trial presented at ATS 2022.

Novel PDE4 inhibitor slows IPF progression

Elaine Soliven, 20220610000000

Treatment with BI 1015550, a novel investigational phosphodiesterase 4 (PDE4) inhibitor, slows lung function decline in patients with idiopathic pulmonary fibrosis (IPF) with or without background antifibrotic therapy, according to a 12-week phase II trial data presented at ATS 2022.

Microwave ablation: a better treatment alternative for NSCLC?

Audrey Abella, 20220608100000

In patients with non-small-cell lung cancer (NSCLC), image-guided thermal ablation (IGTA) via microwave ablation (MWA) appears to deliver better survival benefit compared with another IGTA subtype, radiofrequency ablation (RFA), or stereotactic body radiation therapy (SBRT), according to a systematic review and meta-analysis presented at ATS 2022.

Weight loss intervention may improve COPD symptoms

Roshini Claire Anthony, 20220607170001

In addition to cardiometabolic benefits, a lifestyle intervention aimed at weight loss in patients with chronic obstructive pulmonary disease (COPD) who are overweight or obese may reduce COPD symptoms, according to results of the INSIGHT COPD trial presented at ATS 2022.

Imatinib may reduce mortality in hospitalized COVID-19 patients

Roshini Claire Anthony, 20220606160001

The tyrosine kinase inhibitor imatinib may reduce mortality in patients hospitalized with severe COVID-19, according to follow-up results of the CounterCOVID study presented at ATS 2022.

Step-down therapy may be the better strategy for certain COPD patients

Elvira Manzano, 20220603000000

Switching from triple therapy to dual bronchodilation improves symptom control in patients with chronic obstructive pulmonary disease (COPD) in a new analysis of the DACCORD study.

INCREASE OLE data reflect long-term benefit of inhaled treprostinil for PH-ILD

Audrey Abella, 20220531100000

Findings from the open-label extension (OLE) phase of the INCREASE study boost the efficacy and safety of inhaled treprostinil for pulmonary hypertension due to interstitial lung disease (PH-ILD).

$BLU-5937 may SOOTHE refractory cough$

BLU-5937 may SOOTHE refractory cough

Audrey Abella, 20220530101038

Individuals with refractory chronic cough (RCC) may find relief in BLU-5937, a selective P2X3 antagonist under development which showed favourable efficacy in reducing cough frequency in the phase IIb SOOTHE trial.